Fig 1.
Flow diagram and disposition of the two groups.
Table 1.
Baseline demographics and disease characteristics.
Table 2.
Mean efficacy scores at all time points and change at week 24, and 48 (Mean±SD).
Fig 2.
Scores of ADAS-cog, MMSE, ADL, NPI in YHD and DH group.
A. ADAS-cog scores in groups of YHD and DH; B. MMSE scores in groups of YHD and DH; C. ADL scores in groups of YHD and DH; D. NPI scores in groups of YHD and DH.
Table 3.
Linear mixed effect model estimates of fixed effects (ADAS-cog, MMSE, ADL, NPI).
Table 4.
Reported adverse events.